Cytosorbents Forecasted for 5-Cent Loss Per Share, Revenue Up 7.3% Ahead of Q1 Report
CTSO sits 22% above its 52-week low of $0.499 on light trading volume (0.2× avg).
Summary
Analysts anticipate Cytosorbents Corp will report a loss of 5 cents per share for the quarter ending March 31, 2026, despite an expected 7.3% increase in revenue to $9.363 million. This earnings preview follows the company's recent amended 10-K filing, which disclosed severe liquidity issues, deferred executive bonuses, and going concern warnings. The continued expectation of a loss, even if revenue grows, reinforces the company's challenging financial state and is a material data point for investors. Traders will be watching the actual earnings release on May 13 for confirmation or deviation from these estimates, especially concerning the company's liquidity and profitability outlook.
At the time of this announcement, CTSO was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3M. The 52-week trading range was $0.50 to $1.39. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.